熊去氧胆酸治疗对 COVID-19 自身免疫性肝病患者的影响及其临床预后

IF 3.5 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Biosafety and Health Pub Date : 2024-06-01 DOI:10.1016/j.bsheal.2024.04.004
Minghui Li , Weihua Cao , Tingting Jiang , Wen Deng , Shiyu Wang , Shuling Wu , Lu Zhang , Yao Lu , Min Chang , Ruyu Liu , Xiaoyan Ding , Ge Shen , Yuanjiao Gao , Hongxiao Hao , Xiaoxue Chen , Leiping Hu , Mengjiao Xu , Yuyong Jiang , Wei Yi , Yao Xie , Rui Song
{"title":"熊去氧胆酸治疗对 COVID-19 自身免疫性肝病患者的影响及其临床预后","authors":"Minghui Li ,&nbsp;Weihua Cao ,&nbsp;Tingting Jiang ,&nbsp;Wen Deng ,&nbsp;Shiyu Wang ,&nbsp;Shuling Wu ,&nbsp;Lu Zhang ,&nbsp;Yao Lu ,&nbsp;Min Chang ,&nbsp;Ruyu Liu ,&nbsp;Xiaoyan Ding ,&nbsp;Ge Shen ,&nbsp;Yuanjiao Gao ,&nbsp;Hongxiao Hao ,&nbsp;Xiaoxue Chen ,&nbsp;Leiping Hu ,&nbsp;Mengjiao Xu ,&nbsp;Yuyong Jiang ,&nbsp;Wei Yi ,&nbsp;Yao Xie ,&nbsp;Rui Song","doi":"10.1016/j.bsheal.2024.04.004","DOIUrl":null,"url":null,"abstract":"<div><p>To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (<em>P</em> = 0.003) and immunosuppressant (<em>P</em> = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (<em>P</em> = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (<em>P</em> = 0.018). Logistic regression analysis showed that UDCA use (<em>P</em> = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (<em>P</em> = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (<em>P</em> = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.</p></div>","PeriodicalId":36178,"journal":{"name":"Biosafety and Health","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590053624000545/pdfft?md5=bd6ab21d4a00accdd4ec3b047274df81&pid=1-s2.0-S2590053624000545-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis\",\"authors\":\"Minghui Li ,&nbsp;Weihua Cao ,&nbsp;Tingting Jiang ,&nbsp;Wen Deng ,&nbsp;Shiyu Wang ,&nbsp;Shuling Wu ,&nbsp;Lu Zhang ,&nbsp;Yao Lu ,&nbsp;Min Chang ,&nbsp;Ruyu Liu ,&nbsp;Xiaoyan Ding ,&nbsp;Ge Shen ,&nbsp;Yuanjiao Gao ,&nbsp;Hongxiao Hao ,&nbsp;Xiaoxue Chen ,&nbsp;Leiping Hu ,&nbsp;Mengjiao Xu ,&nbsp;Yuyong Jiang ,&nbsp;Wei Yi ,&nbsp;Yao Xie ,&nbsp;Rui Song\",\"doi\":\"10.1016/j.bsheal.2024.04.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (<em>P</em> = 0.003) and immunosuppressant (<em>P</em> = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (<em>P</em> = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (<em>P</em> = 0.018). Logistic regression analysis showed that UDCA use (<em>P</em> = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (<em>P</em> = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (<em>P</em> = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.</p></div>\",\"PeriodicalId\":36178,\"journal\":{\"name\":\"Biosafety and Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590053624000545/pdfft?md5=bd6ab21d4a00accdd4ec3b047274df81&pid=1-s2.0-S2590053624000545-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biosafety and Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590053624000545\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosafety and Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590053624000545","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨熊去氧胆酸(UDCA)对自身免疫性肝病(AILD)患者严重急性呼吸系统综合征冠状病毒2(SARS-CoV-2)感染和临床预后的影响。研究人员招募了确诊为自身免疫性肝病(AILD)的患者,并根据他们是否接受 UDCA 治疗将其分为 UDCA 组和非 UDCA 组。收集了有关 AILD 诊断、治疗、生化指标和影像学检查的相关数据。观察 AILD 患者的 SARS-CoV-2 感染率和预后。共有 1 138 名患者完成了随访。非 UDCA 组用于治疗 AILD 的激素(P = 0.003)和免疫抑制剂(P = 0.001)的使用率明显低于 UDCA 组。感染 SARS-CoV-2 的患者使用 UDCA 的比例明显低于未感染患者(P = 0.003)。非 UDCA 组的 SARS-CoV-2 感染率明显高于 UDCA 组(P = 0.018)。逻辑回归分析显示,使用 UDCA(P = 0.003)与较低的 SARS-CoV-2 感染率相关,而使用免疫抑制剂(P = 0.017)则会增加感染率。接受 UDCA 治疗的患者从 SARS-CoV-2 感染中恢复的时间明显长于未接受 UDCA 治疗的患者(P = 0.018)。UDCA 可降低 AILD 患者的 SARS-CoV-2 感染率,而免疫抑制剂反而会增加感染率。接受 UDCA 治疗的患者在感染后的恢复时间更长。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis

To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (P = 0.003) and immunosuppressant (P = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (P = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (P = 0.018). Logistic regression analysis showed that UDCA use (P = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (P = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (P = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biosafety and Health
Biosafety and Health Medicine-Infectious Diseases
CiteScore
7.60
自引率
0.00%
发文量
116
审稿时长
66 days
期刊最新文献
Biosafety and immunology: An interdisciplinary field for health priority Advances and challenges of mpox detection technology Construction of pseudotyped human coronaviruses and detection of pre-existing antibodies in the human population Vaccinia virus Tiantan strain blocks host antiviral innate immunity and programmed cell death by disrupting gene expression An outbreak of rhinovirus infection in a primary school in Shenyang City, China, in 2022
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1